<p>Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 获取免费报告) 的股价在周五交易中上涨了 2.7%。该公司的股价最高达到 $6.59，最后交易价为 $6.58。在交易中，共成交 3,679 股，较平均交易量 45,397 股下降了 92%。该股票此前收盘价为 $6.41。</p>
<p>获取 <strong>Armata Pharmaceuticals</strong> 的提醒：</p>
<h2>Armata Pharmaceuticals 股票表现</h2>
<p>该公司的市值为 2.3958 亿美元，市盈率为 -4.06，贝塔系数为 1.24。该股票的 50 日移动平均价格为 $6.07，200 日移动平均价格为 $3.78。</p>
<h2>Armata Pharmaceuticals 的机构交易</h2>
<p>一家机构投资者最近在 Armata Pharmaceuticals 股票中建立了新头寸。GSB Wealth Management LLC 在第二季度购买了 Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 免费报告) 的新股份，根据其最近向 SEC 的披露，该基金购买了 30,000 股公司股票，价值约为 $57,000。GSB Wealth Management LLC 在其最近向 SEC 的备案中拥有 Armata Pharmaceuticals 的 0.08%。目前，3.57% 的股票由机构投资者和对冲基金持有。</p>
<h2>Armata Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Armata Pharmaceuticals, Inc 是一家临床阶段的生物技术公司，开发针对抗生素耐药细菌感染的靶向噬菌体疗法。该公司的专有平台利用自然发生的病毒，选择性地感染并摧毁细菌病原体，提供了一种应对在医院和社区环境中造成重大挑战的耐药菌株的新方法。</p>
<p>Armata 的产品管线包括针对铜绿假单胞菌的噬菌体候选药物，这是一种常见的医院获得性肺炎和囊性纤维化患者感染的病因，以及金黄色葡萄球菌和其他优先病原体。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Armata Pharmaceuticals 更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “$3 人工智能奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Armata Pharmaceuticals 吗？</h2>
<p>在考虑 Armata Pharmaceuticals 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Armata Pharmaceuticals 并不在名单上。</p>
<p>虽然 Armata Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ARMP

<p>Armata Pharmaceuticals (NYSEAMERICAN:ARMP) 的股价上涨了 2.7%，达到了 6.58 美元，尽管交易量下降了 92%。该公司的市值为 2.3958 亿美元，市盈率为-4.06。机构投资者持有该股票的 3.57%。分析师给予买入评级，但建议其他股票可能是更好的投资选择</p>

<p>Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report)'s stock price shot up 2.7% during trading on Friday . The company traded as high as $6.59 and last traded at $6.58. 3,679 shares traded hands during trading, a decline of 92% from the average session volume of 45,397 shares. The stock had previously closed at $6.41.</p>
<div class="lb-trans"><p>Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 获取免费报告) 的股价在周五交易中上涨了 2.7%。该公司的股价最高达到 $6.59，最后交易价为 $6.58。在交易中，共成交 3,679 股，较平均交易量 45,397 股下降了 92%。该股票此前收盘价为 $6.41。</p>
</div><p>Get <strong>Armata Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Armata Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Armata Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Armata Pharmaceuticals 股票表现</h2>
</div><p>The firm has a market capitalization of $239.58 million, a P/E ratio of -4.06 and a beta of 1.24. The stock has a fifty day moving average price of $6.07 and a two-hundred day moving average price of $3.78.</p>
<div class="lb-trans"><p>该公司的市值为 2.3958 亿美元，市盈率为 -4.06，贝塔系数为 1.24。该股票的 50 日移动平均价格为 $6.07，200 日移动平均价格为 $3.78。</p>
</div><h2>Institutional Trading of Armata Pharmaceuticals</h2>
<div class="lb-trans"><h2>Armata Pharmaceuticals 的机构交易</h2>
</div><p>An institutional investor recently bought a new position in Armata Pharmaceuticals stock. GSB Wealth Management LLC purchased a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals as of its most recent filing with the SEC. 3.57% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家机构投资者最近在 Armata Pharmaceuticals 股票中建立了新头寸。GSB Wealth Management LLC 在第二季度购买了 Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 免费报告) 的新股份，根据其最近向 SEC 的披露，该基金购买了 30,000 股公司股票，价值约为 $57,000。GSB Wealth Management LLC 在其最近向 SEC 的备案中拥有 Armata Pharmaceuticals 的 0.08%。目前，3.57% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Armata Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Armata Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.</p>
<div class="lb-trans"><p>Armata Pharmaceuticals, Inc 是一家临床阶段的生物技术公司，开发针对抗生素耐药细菌感染的靶向噬菌体疗法。该公司的专有平台利用自然发生的病毒，选择性地感染并摧毁细菌病原体，提供了一种应对在医院和社区环境中造成重大挑战的耐药菌株的新方法。</p>
</div><p>Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.</p>
<div class="lb-trans"><p>Armata 的产品管线包括针对铜绿假单胞菌的噬菌体候选药物，这是一种常见的医院获得性肺炎和囊性纤维化患者感染的病因，以及金黄色葡萄球菌和其他优先病原体。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Armata Pharmaceuticals</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Armata Pharmaceuticals 更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “$3 人工智能奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Armata Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Armata Pharmaceuticals 吗？</h2>
</div><p>Before you consider Armata Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Armata Pharmaceuticals 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Armata Pharmaceuticals 并不在名单上。</p>
</div><p>While Armata Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Armata Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Armata Pharmaceuticals（NYSEAMERICAN:ARMP）股价上涨 2.7% - 现在仍然值得购买吗？